IPF Ofev denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for ipf ofev are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Ofev (nintedanib) for IPF as Experimental

Despite Ofev holding FDA approval for idiopathic pulmonary fibrosis, Cigna occasionally applies an "experimental or investigational" denial when the coverage policy review cycle has not yet aligned with a new indication, when the drug is being prescribed for a closely related but distinct fibrotic condition under the same ICD code, or when the claim lacks the documentation that Cigna's clinical editing system requires to confirm the on-label use. This denial is one of the most straightforwardly reversible in the IPF context because the FDA-approval history is unambiguous.

## Why This Denial Is Appealable

FDA approval for the specific indication being treated is the clearest possible rebuttal to an experimental denial. Cigna's own coverage policies generally align approved indications with covered uses. The appeal record simply needs to make the connection explicit: confirmed IPF diagnosis plus on-label use plus prescriber attestation.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe printed on your Explanation of Benefits. Cigna must issue a decision within 30 days (non-urgent) or 72 hours (expedited).
• External review (ACA §2719): Available after an adverse internal decision or deemed denial. An independent review organization will evaluate whether Cigna's experimental determination is consistent with the FDA label and with coverage science. The request window is typically up to four months from the denial notice.
• ERISA §503: For employer-sponsored plans, federal law requires a full-and-fair review of all evidence you submit.
• Expedited review: Request this if your prescriber documents that a delay would jeopardize your health or your ability to regain maximum function.

## Documentation to Gather

1. FDA approval documentation — The prescriber letter should reference Ofev's FDA-approved indication for IPF and confirm the patient's diagnosis matches that indication. 2. Diagnosis confirmation — Pulmonologist or specialist records with an ICD-coded IPF diagnosis, supported by imaging and pulmonary function testing. 3. On-label use statement — A clear statement from the prescriber that the prescribed use is consistent with the FDA-approved labeling; direct Cigna to the current FDA-approved prescribing information. 4. Applicable guideline reference — The prescriber may reference the relevant professional society guideline organization (e.g., the applicable ATS/ERS guideline for IPF management) without quoting specific numbers. 5. Prior-treatment history — If any prior IPF therapies were trialed, document dates and outcomes to establish clinical context.

## Criteria-Mapping Structure

Obtain Cigna's published experimental/investigational coverage policy and its antifibrotic coverage policy. For each criterion listed, provide a direct chart citation:

• FDA approval status for the claimed indication — cite the prescribing label
• Confirmed diagnosis matching the approved indication — cite specialist records
• Prescriber qualifications and clinical rationale — cite the medical-necessity letter
• Absence of a superior, less experimental alternative — cite prior treatment history and guideline organization recommendations

A concise side-by-side table submitted with the internal appeal letter typically resolves this denial without needing to escalate to external review.